Prior Art Search
It focuses on the most current innovations, prior art searches delve into historical records of patents and technical literature. These searches help establish the novelty and non-obviousness of an invention when filing for patents.
Biological Sequences include DNA/RNA nucleotide sequences or amino acid sequences of protein. Searching for Bio-sequences includes finding a specific arrangement of sequences in a given patent or non-patent document. Sequence search helps the inventors to ascertain whether the sequence is novel or not. Since the novelty of the sequence lies in the unique combination of nucleotides or amino acids, a keywords-based search alone cannot capture the entire data-set including all the relevant results. Even if the desired sequence has a common name, not all patents would include the name, and thus a number of such results may be missed during the keyword-based search.
Some of the key tools used for sequence searching are – STN (Scientific Technical Networks), which is a network of more than 200 databases, BLAST searching, etc. Sequence searching requires deep domain expertise in the databases such as STN.
We at Effectual Services, have a team of Bio-technology experts who specialize in sequence searching. Over the years we have developed an in-depth understanding of the workings of these databases and have derived strategies to derive the expected output within a minimal budget.
The search query typically begins with a Bio-sequence representation, which is usually provided in FASTA Format depicting the arrangement of nucleotides or amino acids. A Bio-sequence itself can contain several sub-sequences. For example, the presence of a Heavy constant sequence and Heavy variable sequence within the Heavy chain sequence of the antibody.
Bio-sequence search relies on specialized search algorithms and databases capable of identifying the sequences matching the query provided based on the algorithm and scoring matrix chosen. There are a few free databases such as GenBank from NCBI (National Center for Biotechnology Information), SwissProt from the Swiss Institute of Bioinformatics, and PIR from the Protein Information Resource. The paid database includes STN, and Bio-sequence search from Questel Orbit.
Users can specify matching criteria, such as Sequence Identity and Query cover, or other specific requirements depending on the search's purpose. Furthermore, the matching criteria can be selected on the basis of sequence length.
The methodology of bio-sequence search involves broadly scoping, understanding, searching, analysis, and reporting.
The search is conducted for the granted patents and published patent applications filed worldwide.
We develop an understanding of the objective and scope of the project, and the technology domain.
We perform a comprehensive search on patent databases (pertinent to the technical domain), using a variety of strategies such as –
On the patents side, we use one or more of the following patent databases: Orbit (from Questel), Totalpatent (from Lexis Nexis, covers ~100 jurisdictions worldwide), Patseer, Derwent Innovation (covers ~100 jurisdictions worldwide), Google patent, and Espacenet.
A detailed analysis of the identified results (from Step 3 above) is performed in order to locate the key references. We will analyze references disclosing sequence(s) with a specific ‘% Identity’ and ‘% Query Coverage’ to capture the references covering the above listed objective of the study.
There are several compelling reasons to choose Effectual Services for your Bio-sequence search needs
"At Effectual, we have successfully delivered 500+ Bio-sequence worldwide in various branches of science for gathering and analyzing the latest advancements and innovations in specific scientific fields such as biotechnology, Pharma etc.
As a leader in IP services, we bring proven expertise, cutting-edge technology, and a commitment to your success.
Join hands with us and experience the difference. Contact us today to explore how we can make your projects a resounding success!
Call to ActionA leading pharmaceutical drug manufacturer, sought to identify similar antibody sequence for the treatment of feline Pruritus.
Feline pruritus, commonly known as itching or scratching in cats, is a distressing condition characterized by persistent and intense itching of the skin. This condition can lead to skin lesions, infections, and a reduced quality of life for affected felines. Feline pruritus can result from various underlying causes, including allergies, parasitic infestations, dermatitis, and systemic diseases.One promising approach to alleviate the suffering of cats with pruritus is the development of targeted antibody-based therapies and our aim is to identify sequences of antibody capable of treatment of feline pruritus.
Identified the Patent and non-patent references disclosing the antibody sequence with atleast 98% sequence similarity and 98% query coverage.
Used keywords to narrow down the scope of the search.
A pioneering biotechnology company, aimed to develop a groundbreaking cancer therapy that hinged on the creation of a synthetic biomolecule. Their objective was to engineer an artificial biomolecule with a precise binding sequence to target and disrupt a specific cancer receptor's signaling pathway, ultimately halting tumor growth.
Cancer remains one of the most formidable challenges in healthcare worldwide, with its diverse and complex nature necessitating a multifaceted approach to treatment. Traditional cancer therapies, such as chemotherapy and radiation, often lack specificity. These synthetic biomolecules, which can take the form of peptides, antibodies, or other molecular entities, are engineered with a specific purpose: to selectively interact with cancer receptors found on the surface of cancer cells.
The process of identifying a synthetic sequence within an artificial biomolecule capable of binding to a cancer receptor is a multidisciplinary undertaking. The aim of this study was to identify all the synthetic bio-molecules capable of binding to the Receptor of interest.
We conducted a comprehensive analysis that involved the identification of both patented and non-patented references detailing synthetic biomolecules designed to bind to cancer receptors for potential cancer treatment applications.
Moreover, we delved into an in-depth evaluation of the efficacy and potential side effects associated with these synthetic biomolecules, sourcing our information from clinical trial databases.
In addition, we explored the various modes of delivery for these biomolecules, including innovative approaches such as lipid nanoparticles and sustained-release formulations.
A technology start-up in ocular healthcare solutions, aimed to identify patents related to antibody targeting a receptor. The binding of antibody to the receptor results in the treatment of dry eye syndrome. The objective was to locate all patents held by the assignee that cover the antibody and its production method, its sequence, methods of treatment, or its formulation.
A biosimilar is a biological product that is highly similar to a reference or originator biological product, but not identical. These biological products are typically large, complex molecules derived from living organisms, such as proteins, antibodies, or other biologics. Biosimilars are designed to have similar efficacy, safety, and quality to the reference product, and they are used to treat a wide range of diseases and medical conditions.
Our team conducted an exhaustive patent search focused on bio-sequences related to the antibody. We conducted a detailed analysis, utilizing specific keywords, and narrowed the search scope exclusively to applications pertaining to the treatment of dry eyes.
We also conducted an extensive investigation into the manufacturing contracts, collaborative partnerships, and regulatory clearance processes involved in bringing the antibody to market.